If you made any changes in Pure these will be visible here soon.

Research Output 2011 2019

  • 858 Citations
  • 12 h-Index
  • 38 Article
  • 4 Review article
  • 1 Letter
Filter
Review article
2018
2 Citations (Scopus)

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Iwama, E., Nakanishi, Y. & Okamoto, I., Mar 4 2018, In : Expert Review of Anticancer Therapy. 18, 3, p. 267-276 10 p.

Research output: Contribution to journalReview article

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Therapeutics
2015

Clinical benefits associated with first line treatment using afatinib

Iwama, E. & Okamoto, I., Oct 20 2015, In : Japanese Journal of Lung Cancer. 55, 6, p. 866-870 5 p.

Research output: Contribution to journalReview article

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Therapeutics
Mutation
Paronychia
2014
1 Citation (Scopus)

[Personalized medicine in non-small-cell carcinoma].

Iwama, E., Takayama, K., Baba, E. & Nakanishi, Y., Jan 1 2014, In : Fukuoka igaku zasshi = Hukuoka acta medica. 105, 3, p. 57-66 10 p.

Research output: Contribution to journalReview article

Serine Endopeptidases
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-ret
Antineoplastic Combined Chemotherapy Protocols
Molecular Targeted Therapy
31 Citations (Scopus)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer

Iwama, E., Okamoto, I., Harada, T., Takayama, K. & Nakanishi, Y., Mar 5 2014, In : OncoTargets and Therapy. 7, p. 375-385 11 p.

Research output: Contribution to journalReview article

Lung Neoplasms
Non-Small Cell Lung Carcinoma
anaplastic lymphoma kinase
United States Food and Drug Administration
Oncogenes